Report copyright - Investor Meeting on FY2016 Results and FY2017 Forecasts · Growth on acquired Merck products and Ikervis: +11.3% (JPY), +23.9% (local currency) Surgical NPM +5.6% growth supported
Please pass captcha verification before submit form